TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity


Thiesen, Signe, Yin, Peng, Jorgensen, Andrea L ORCID: 0000-0002-6977-9337, Zhang, Jieying E ORCID: 0000-0003-1813-2207, Manzo, Valentina, McEvoy, Laurence ORCID: 0000-0002-2169-6735, Barton, Christopher, Picton, Susan, Bailey, Simon, Brock, Penelope et al (show 7 more authors) (2017) TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity PHARMACOGENETICS AND GENOMICS, 27 (6). pp. 213-222. ISSN 1744-6872, 1744-6880

[thumbnail of Cispatin paper_clean.docx] Text
Cispatin paper_clean.docx - Author Accepted Manuscript
Download (94kB)
[thumbnail of Tables_updated.docx] Text
Tables_updated.docx - Author Accepted Manuscript
Download (38kB)
[thumbnail of Figure 1 Pharmacogenetics and genomics.docx] Text
Figure 1 Pharmacogenetics and genomics.docx - Author Accepted Manuscript
Download (72kB)
[thumbnail of Supplementary data .docx] Text
Supplementary data .docx - Author Accepted Manuscript
Download (117kB)

Abstract

Objectives Cisplatin ototoxicity affects 42-88% of treated children. Catechol-O-methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic variants have been associated with ototoxicity, but the findings have been contradictory. The aims of the study were as follows: (a) to investigate these associations in a carefully phenotyped cohort of UK children and (b) to perform a systematic review and meta-Analysis. Methods We recruited 149 children from seven UK centres using a retrospective cohort study design. All participants were clinically phenotyped carefully. Genotyping was performed for one ACYP2 (rs1872328), three TPMT (rs12201199, rs1142345 and rs1800460) and two COMT (rs4646316 and rs9332377) variants. Results For CTCAE grading, hearing loss was present in 91/120 (75.8%; worst ear) and 79/120 (65.8%; better ear). Using Chang grading, hearing loss was diagnosed in 85/119 (71.4%; worst ear) versus 75/119 (63.0%; better ear). No TPMT or COMT single-nucleotide polymorphisms (SNPs) were associated with ototoxicity. ACYP2 SNP rs1872328 was associated with ototoxicity (P=0.027; worst ear). Meta-Analysis of our data with that reported in previous studies showed the pooled odds ratio (OR) to be statistically significant for both the COMT SNP rs4646316 (OR: 1.50; 95% confidence interval: 1.15-1.95) and the ACYP2 SNP rs1872328 (OR: 5.91; 95% confidence interval: 1.51-23.16). Conclusion We showed an association between the ACYP2 polymorphism and cisplatin-induced ototoxicity, but not with the TPMT and COMT. A meta-Analysis was statistically significant for both the COMT rs4646316 and the ACYP2 rs1872328 SNPs. Grading the hearing of children with asymmetric hearing loss requires additional clarification.

Item Type: Article
Uncontrolled Keywords: ACYP2, cancer, catechol-O-methyltransferase, cisplatin, ototoxicity, paediatric cancer, pharmacogenetics, thiopurine methyltransferase
Depositing User: Symplectic Admin
Date Deposited: 25 Apr 2017 06:33
Last Modified: 23 May 2026 00:44
DOI: 10.1097/FPC.0000000000000281
Related Websites:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3007119
Disclaimer: The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.
Altmetric
CORE (COnnecting REpositories)